EQT has agreed to acquire Qiagen in a deal valued at about €10.8 billion (roughly $12.1 billion) in cash, pushing the life sciences tools and diagnostics provider into private ownership. The transaction follows multiple takeover approaches over years. Qiagen’s boards said an EQT-backed buyout offers the best path for its next growth phase, citing flexibility for longer-term investment. The offer structure includes co-investor stakes via Luxinva (Abu Dhabi Investment Authority) and CPP Investment Board Europe (CPP Investments). The announcement follows a strategic review and market interest that lifted Qiagen shares to multi-year highs. Completion is still subject to shareholder approval and closing conditions, with the company expected to keep its name and operate independently until the deal closes.